News Release Fujirebio Confirms its Engagement in Blood-based Alzheimer s Disease Biomarker Testing with the Launch of the Fully Automated Lumipulse® G. | March 30, 2022
Data from Lilly at International Conference on Alzheimer s & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer s Disease Research
Highlights include results from the Phase 2 Trailblazer-ALZ study for donanemab
News provided by
Share this article
Share this article
INDIANAPOLIS, March 9, 2021 /PRNewswire/ New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer s & Parkinson Diseases
™ 2021 (AD/PD
™ 2021), March 9-14, 2021. Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer s disease (AD) compared to placebo. Additional data highlight Lilly s AD program focused on developing both disease-modifying therapies that slow clinical progression by targeting t